Additional information
| Active substance | Dabigatran |
|---|---|
| Water Retention | No significant water retention |
| Hepatotoxicity | No significant hepatotoxicity |
| Lab Test | Monitoring of renal function and possibly coagulation parameters |
| Also known as | Dabigatran |
| Blood pressure | Typically does not affect blood pressure |
| Trade name | Pradaxa |
| FORM | 60 caps x 75 mg |
| Storage conditions | Store at room temperature away from moisture and heat |
| Chemical name | N-{2-[4-(N'-{[(Hexyloxy)carbonyl]carbamimidoyl}carbamimidoyl)phenylaminomethyl]-1-methyl-1H-benzimidazol-5-ylcarbonyl}-N-pyridin-2-yl-beta-alanine ethyl ester |
| Formula | C34H41N7O5 |
| Substance class | Direct thrombin inhibitor |
| Main action | Anticoagulant |
| Half-life | 12 to 17 hours |
| Dosage (medical) | 150 mg or 110 mg twice daily depending on renal function |
| Dosage (sports) | Not applicable as it is not used for sports enhancement |
| Effects | Reduces the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation |
| Side effects | Bleeding, gastrointestinal upset, heartburn, nausea |
| Use in sports | None, as it does not enhance athletic performance |
| Manufacturer | Boehringer |

Zyban Glaxosmithkline
LIOTHROW cRowX Labs
Fostimon (Merional) 75 (HMG) IBSA
FACTIVE 320 mg Abdi Ibragim
Prograf 1mg Astellas Pharma
Fostimon (Merional) 150 IU HMG IBSA
Enbrel Flakon Pfizer
CANTAB PLUS 32/12.5 mg Nobel
Norvacs 10 mg Pfizer
AVELOX 400 Bayer
Rovamycine 3.000.000 iu Eczacibasi 

Reviews
There are no reviews yet.